Get the Stockscreener App
108.07
2.17%
-2.40
Pre-market:
107.70
-0.37
-0.34%
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $108.07, with a volume of 1.35M.
It is down -2.17% in the last 24 hours and down -4.38% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$110.47
Open:
$110.84
24h Volume:
1.35M
Relative Volume:
0.91
Market Cap:
$12.06B
Revenue:
$2.90B
Net Income/Loss:
$239.11M
P/E Ratio:
51.23
EPS:
2.1097
Net Cash Flow:
$492.62M
1W Performance:
+1.53%
1M Performance:
-4.38%
6M Performance:
-5.71%
1Y Performance:
+4.24%
1-Day Range:
$107.48
$111.25
1-Week Range:
$102.36
$116.00
52-Week Range:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
108.07 | 12.06B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
559.53 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.50 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
556.20 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
137.89 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
258.03 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Revvity Inc. stock underperforms Monday when compared to competitors - MarketWatch
Revvity Inc (RVTY) Cash Flow - TradingKey
Revvity Market Sentiment - Benzinga España
Revvity Inc (RVTY) Income Statement - TradingKey
RVTY|Revvity Inc|Price:111.500|Chg%:+1.030 - TradingKey
Revvity Inc (RVTY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revvity, Inc. (RVTY) Stock Analysis: Potential Upside and Solid Revenue Growth in the Healthcare Sector - DirectorsTalk Interviews
Revvity Inc (RVTY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revvity stock holds firm as diagnostics and life sciences revenue support valuation - Ad-hoc-news.de
PKI5144058 Bond Risk Profile - TradingView
RVTY|Revvity Inc|Price:110.470|Chg%:-2.700 - TradingKey
Revvity, Inc. (RVTY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revvity, Inc. (RVTY) stock price, news, quote and history - Yahoo Finance Australia
Revvity, Inc. (RVTY) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
PKI5144058 Bond Profile — Key Metrics - TradingView
Revvity, Inc. (RVTY) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Revvity, Inc. (RVTY) Stock Forecasts - Yahoo! Finance Canada
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs - Zacks Investment Research
Revvity Inc (RVTY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Revvity Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs - Yahoo Finance
Revvity Inc (RVTY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Sell Alert: Anita Gonzales Sells Shares of Revvity Inc (RVTY) - GuruFocus
Revvity (NYSE: RVTY) VP Gonzales sells 85 shares under 10b5-1 plan - Stock Titan
How Revvity’s (RVTY) Startup Software Push and ESG Disclosures Reframe Its Competitive Positioning - simplywall.st
Revvity to Launch Signals for Startups for Emerging Biotech Companies - The Globe and Mail
Revvity, Inc. (PKN) Q3 2022 Earnings ReportResults, Call & Slides - TipRanks
Revvity (RVTY) 10K Form and Latest SEC Filings 2026 - MarketBeat
Revvity Inc. Stock Slides 3.4%, Underperforms Peers - webull.com
Revvity stock holds steady as Q1 2026 growth and margin expansion underpin valuation - Ad-hoc-news.de
Precision Trading with Revvity Inc. (RVTY) Risk Zones - Stock Traders Daily
Revvity Inc (RVTY) Stock Down 3.4% -- Now Undervalued? GF Score: 72/100 - GuruFocus
Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One - 01net
Revvity (RVTY) Receives a Buy from Leerink Partners - The Globe and Mail
RVTY (RVTY) investor files notice to sell 85 common shares - Stock Titan
Revvity (NYSE: RVTY) removes 1.875% notes due 2026 from NYSE listing - Stock Titan
Revvity launches “Signals for Startups” to give emerging biotechs an enterprise-grade digital edge - Indian Chemical News
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure - Lelezard
Revvity stock trades steadily as recent earnings highlight margin focus - AD HOC NEWS
PKI5144059 Bond Coupon Profile — Rate & Payments - TradingView
PKI5144059 Bond Profile — Key Metrics - TradingView
XS1405780617 Bond Coupon Profile — Rate & Payments - TradingView
XS1405780617 Bond Risk Profile - TradingView
PKI5255604 Bond Risk Profile - TradingView
XS1405780617 Bond Profile — Key Metrics - TradingView
Revvity stock trades steady as genomics and diagnostics revenue underpins valuation - Ad-hoc-news.de
Revvity, Inc. (PKN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Revvity, Inc. (PKN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
PKI5255604 Bond Profile — Key Metrics - TradingView
PKI5255604 Bond Coupon Profile — Rate & Payments - TradingView
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):